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Background: Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies
and yet there are potential treatment options for patients after standard treatment escape. The French Sarcoma
Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of patients
treated with off-label TTs.
Methods: Every consecutive sarcoma-patient receiving an off-label TT outside a clinical trial was included. The
objective was to describe this patient efficacy and safety data in routine practice.
Results: From October 2008 to October 2011, 249 patients in 24 centers received 278 treatment lines with TTs.
Twenty-five histological subtypes were included: most frequent were leiomyosarcoma (n = 48, receiving sorafenib
in 63%, and sunitinib in 27%), GIST (n = 39, receiving sorafenib in 79%), and angiosarcoma (n =18, receiving
sorafenib in 78%). The overall response rate to TTs was 15% (95% CI [10,6-20,2]), the disease control rate at 2 months
was 59%. The median progression-free survival was 4,1 months (IC 95% [3,2-4,8]). Three complete responses were
observed. No toxic death occurred, grade 3 and 4 toxicities were reported in 74 (27%) and 14 patients (5%)
respectively.
Conclusion: Off-label TTs can be used for sarcoma patients in routine practice with an acceptable toxicity profile
and efficacy similar to that reported in non-randomized clinical trials.
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Soft tissue sarcomas (STS) are rare tumors with an inci-
dence of 6/100000/year [1,2]. Patients with metastatic
sarcoma have a poor prognosis and their median overall
survival (OS) doesn’t exceed 18 months [3]. More than
50 histological subtypes have been identified and their
diagnosis often requires an expert review [4]. In the last
two decades, progress in molecular biology have lead to
a better understanding of sarcomas biology and ontology,
though with limited therapeutic implications since the
standard treatment of metastatic sarcoma remains che-
motherapy, regardless of specific molecular alterations [5].* Correspondence: isabelle.ray-coquard@lyon.unicancer.fr
1Centre Léon Bérard, 28 rue Laennec 69 373, LYON CEDEX 08, France
2Université Claude Bernard Lyon 1, Lyon, France
Full list of author information is available at the end of the article
© 2014 Eberst et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.The registered cytotoxic agents are anthracyclines, ifos-
famide, dacarbazine and trabectedin. The gemcitabine-
docetaxel and gemcitabine-dacarbazine combinations have
also been reported as active treatments in some histo-
logical subsets [6-9]. These regimens are cited as options
in clinical practice guidelines from the European Society
for Medical Oncology (ESMO) [10] or the National Com-
prehensive Cancer Network (NCCN) [11].
However, the success of imatinib in gastro-intestinal
stromal tumors (GISTs) showed the relevance of guiding
treatment to specific molecular alterations [12] and simi-
lar observations have been obtained in other rare histo-
logical sarcoma subtypes [13,14], leading to the approval
of several targeted therapies (TTs). Imatinib, a multi-
target tyrosine-kinase inhibitor, and aside form GIST has
been shown to have activity in several sarcoma subtypestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tein product of the COL1A1-PDGFB fusion transcript in
dermatofibrosarcoma protuberans (DFSP) [15,16] and
the colony-stimulating factor 1 in pigmented vilonudular
synovitis [17]. Its mechanism of action remains unclear
in aggressive fibromatosis (AF), but several phase II
trials confirmed its activity [18,19]. Denosumab has been
approved for the treatment of giant-cell tumor of bone,
it blocks tumor-induced bone destruction by inhibiting
RANK-RANK-ligand interaction [20]. However, there is
no known actionable molecular alteration in the vast
majority of sarcomas. Overall sarcomas are difficult to
study because of their heterogeneity. This may explain
why several phase II trials testing TTs for STS (imatinib
[21], sorafenib [22], sunitinib [23]) haven’t lead to re-
gistration or to phase III trials despite signs of potential
activity. Pazopanib was recently approved by both the
Food and Drug Administration and European Medecines
Agency following the positive results of the Palette study
[24]. Ridaforolimus on the other hand was not approved
despite a positivity of the SUCCEED trial [25].
It’s not unusual, according to medical practice analysis,
that patients with advanced sarcoma receive four or more
lines of treatment [26], TTs are then interesting treatment
options when patients experience disease progression des-
pite standard treatments. Because several commercially
available agents had shown signs of activity in sarcomas in
retrospective and prospective phase II studies, the French
Sarcoma Group setup a national registry in 2008. This
registry, called OUTC’S (Observatoire de l’Utilisation des
Thérapies Ciblées dans le Sarcome/Observatory for the
use of targeted therapies in sarcomas), aimed to collect in
a prospective manner all medical data regarding the use of
off-label TTs in sarcoma and assess their activity in rou-
tine practice. Off-label prescription is authorized in France
for rare disease under control of experts, based on pub-
lished data reporting potential activity. The objectives of
this study were to analyse the activity and toxicity of TTs
in sarcoma and eventually identify specific subsets of pa-
tients responding to a particular TT in a given histological
subtype. This registry could hence be useful for a better




Patients with the following criteria were included: sar-
coma with confirmed histological diagnosis, not amen-
able to curative treatment, treatment in France with
non-approved TT (i.e. a drug interfering with a specific
molecular target) and outside any clinical trial. GIST pa-
tients treated with imatinib or sunitinib were excluded
(these drugs had already been approved). In spite of the
recent approval of imatinib for DFSP and because moreclinical data was needed, patients treated with imatinib
were included, as well as bone sarcoma patients treated
with zoledronic acid, considering promising results of
this treatment as TT in preclinical models of bone sar-
comas [27,28]. As the study was not interventional, for-
mal written consent was not required by French law.
However, patients were informed and gave oral consent
for data collection and use of clinical data for research
purposes. Children could be included with their parents’
consent. All patients received a detailed information let-
ter and had the opportunity to withdraw their consent at
any time.
Competent authorities approval
All data was collected by the coordination center (Centre
Léon Bérard, Lyon) after approval of the Centre Léon
Bérard Clinical Trial Review Committee and the French
data protection authority (CNIL). The study had to be ap-
proved by the Multidisciplinary Sarcoma Board (MSB) of
all participating centers (Additional file 1: Participating
centers) according to the French Cancer Plan recommen-
dations (2003–2007). Most decisions of off-label TT treat-
ment were made after patients were discussed at a MSB,
as defined by the French SARComa NETwork (Netsarc
[29]) including at least three experts. Eighteen compre-
hensive cancer centers and eight university hospitals (all
members of the GSF-GETO) participated and included all
consecutive patients if they met inclusion and exclusion
criteria (two centers did finally not include any patient).
Once a patient was registered, follow-up was established
every two months by the coordination center.
Data collection and study endpoints
The primary objective of this study was to describe the ef-
ficacy of off-label TTs in sarcoma-patients. Secondary ob-
jectives included characterization of toxicity, feasibility of
such off-label prescription in routine practice and descrip-
tion of unique exceptional responses in particular sarcoma
subtypes. Data was collected from clinical files. Efficacy
endpoints included response rate (RR) to a given TT, over-
all response rate to treatment (ORR) (i.e. rate of complete
and partial responses [CR, PR] according to RECIST cri-
teria [30]), disease control rate at two, four and six months
(i.e. rate of CR and PR and stable disease [SD] as best
overall response), PFS under treatment and OS.
Statistical methods
The ORR was calculated with its 95% confidence interval
(CI). PFS was calculated from the beginning of TT to the
date of event, defined as the first documented progression
under treatment or death due to any cause under treat-
ment. Patients who did not experience an event were cen-
sored at the date of treatment and in cases of premature
treatment discontinuation, before the end of follow-up or
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ment. OS was calculated from the date of diagnosis until
the date of death due to any cause and censored at the
date of last contact for patients alive. PFS and OS were
estimated by the Kaplan-Meier method. Safety evaluation
was based on the frequency and severity of toxicities,
graded according to the Common Terminology Criteria
for Adverse Events (AE) [31].
Patients could be included more than one time in the
registry when receiving consecutive lines of TTs. All
analyses were performed on total number of treatment
lines (expressed as ‘patients’ when described), except for
data regarding OS, which was analysed on the total
number of patients included at least once in the study.
For patients included several times, OS was calculated
as the time between initial diagnosis and date of last
follow-up for the latest treatment. The research database
was locked for the statistical analysis in October 2011.




From October 2008 to October 2011, 249 patients in 24
institutions were registered and received a total of 278
lines of treatment (21 and 4 patients received two and
three successive lines of TT respectively). The popula-
tion characteristics are presented in Table 1. The median
time from sarcoma diagnosis to treatment in the registry
was 3.5 years (range 15 days to 32 years). The median
number of previous systemic therapy (chemotherapy)
was three (range 0–9). Fifteen patients received a TT as
their first line of systemic therapy. In all cases these patients
had a sarcoma subtype or connective tissue tumor with no
other standard option (AF, angiosarcoma, chordoma…),
and were treated with imatinib, sorafenib, or mTOR
inhibitors. First line treatment is detailed in Additional
file 2: Table S1). A median number of three lines of
chemotherapy (range 0–9) was administered before star-
ting TT. At the time of initiation of TT, 70% of patients
had a documented RECIST progressive disease on their
previous treatment. The decision to use off-label TT was
made after discussion in MSB for 203 patients (76%).
Efficacy of off-label targeted therapy
Sorafenib was used for 125 patients (45%) as a single agent
(n = 120) or with dacarbazine (n = 3), metformine (n = 1),
or paclitaxel (n = 1). Sunitinib was used for 67 patients
(24%), including one case of sunitinib combined with
cyclophosphamide. Sirolimus was given to 25 patients
(9%), in most cases in combination with cyclophospha-
mide (n = 18). Imatinib was used as single agent in 23 pa-
tients (8%), and in combination with everolimus (n = 3).
Other TTs were everolimus (n = 10), bevacizumab (n = 9),temsirolimus (n = 4), nilotinib (n = 3), pazopanib (n = 2),
zoledronic acid (n = 2), enzastaurin (n = 2), crizotinib,
cetuximab, erlotinib, masitinib, panobinostat, and deforo-
limus (one patient each). Table 2 describes the most fre-
quent TTs by major subtypes.
Among the 39 patients with GISTs, 31 were treated
with sorafenib and the RR was 10% (3 PRs), three were
treated with nilotinib, and three with the combination
everolimus-cyclophosphamide. The other prescribed TTs
for this histotype were masitinib (n = 1) and sunitinib-
cyclophosphamide combination (n = 1). Among the 36
patients with non-uterine leiomyosarcoma (LMS), sorafe-
nib was used in 22 cases with a RR of 14% (3 PRs), suniti-
nib in nine cases with a RR of 22% (2 PRs). The other
patients were treated with everolimus (n = 3), imatinib
(n = 1), and enzastaurin (n = 1). On the 18 angiosarcoma
patients, 14 were treated with sorafenib with a RR of 21%
(3 PRs), two were treated with sunitinib and the RR was
50% (1 PR). The remaining two patients were treated with
bevacizumab-paclitaxel and sirolimus-cyclophosphamide
combinations. Among the 15 patients with an unclassified
sarcoma, eight were treated with sunitinib with a RR of
13% (1 PR), five were treated with sorafenib, one was
treated with imatinib and one with panobinostat. Among
15 patients with chordoma, eight received imatinib, three
received sunitinb, two received sorafenib, and one re-
ceived sirolimus combined with cyclophosphamide. One
patient with chordoma treated with erlotinib had a PR. Of
15 patients with osteosarcoma, ten were treated with siro-
limus (including eight cases treated with sirolimus com-
bined with cyclophosphamide), three were treated with
sorafenib, and two with sunitinib. Among the 15 patients
with synovial sarcoma (SS), eight were treated with suniti-
nib with a RR of 50% (4 PRs), three with sorafenib, two
with pazopanib with a RR of 50% (1 PR), one with everoli-
mus and one with cetuximab. For 125 patients with other
histological subtypes comprising less than 15 patients
each, TTs are described in Table 3.
More generally, the ORR of TTs for the whole group
was 15% (95% CI [10,6-20,2]). Three patients had a CR:
one patient with PEComa treated with temsirolimus
who achieved a CR after seven months and stopped TT
two months later because of continuing CR. The second
patient was treated with sunitinib for a Ewing sarcoma.
He stopped sunitinib after two months treatment. One
patient with DFSP also achieved a CR with imatinib after
five months of treatment. Thirty-two PRs were observed
in 16 different subtypes with various TTs (17% of pa-
tients treated with sunitinib, 14% with sorafenib, 9% with
imatinib, and 6% with sirolimus). CRs, PRs and corre-
sponding TTs are described in Table 3. RRs superior to
20% were observed for DFSP with imatinib (75%, n = 4),
for SS with sunitinib (50%, n = 8), for alveolar soft parts
sarcoma with sorafenib (40%, n = 5), for non-uterine




Male (%) 153 (55.0)
Female (%) 125 (45.0)
Age at initial histological diagnosis (years)
Mean (SD) 42.7 (17.8)
Median (min-max) 45.0 (6–81)
Unknown/missing data (%) 1 (0.4)
Age at beginning of TT (years)
Median (min-max) 49.0 (8–81)
≤18 years (%) 16 (5.8)
≥70 years (%) 36 (12.9)
Tumor localization
Abdomen (%) 60 (21.6)
Lower limb (%) 53 (19.2)
Pelvis (%) 37 (13.3)
Thorax (%) 36 (12.9)
Axial skeletton (%) 26 (9.3)
Upper limb (%) 24 (8.7)
Head/neck (%) 20 (7.2)
Retroperitoneum (%) 20 (7.2)
Unknown (%) 2 (0.7)
Histological subtype
GIST (%) 39 (14.1)
Leiomyosarcoma (%) 36 (13.0)
Angiosarcoma (%) 18 (6.5)
Unclassified sarcoma (%) 15 (5.4)
Chordoma (%) 15 (5.4)
Osteosarcoma (%) 15 (5.4)
Synovialosarcoma (%) 15 (5.4)
Ewing/PNET (%) 14 (5.1)
Chondrosarcoma (%) 12 (4.3)
Uterine leiomyosarcoma (%) 12 (4.3)
Liposarcoma (%) 12 (4.3)
Solitary fibrous tumor (%) 10 (3.6)
Epithelioid sarcoma (%) 9 (3.2)
MPNST (%) 8 (2.9)
ASPS (%) 8 (2.9)
DSRCT (%) 6 (2.1)
Aggressive fibromatosis (%) 6 (2.2)
DFSP (%) 5 (1.8)
PEComa (%) 4 (1.4)
Rhabdomyosarcoma (%) 3 (1.1)
Kaposi sarcoma (%) 1 (0.4)
Table 1 Population characteristics (Continued)
Low grade endometrial stromal sarcoma (%) 1 (0.4)
Phyllode tumor (%) 1 (0.4)
Other (including benign tumors) (%)** 13 (4.7)
Tumor grade
Unknown (%) 93 (33.4)
Non evaluable (%) 27 (9.7)
Grade I (%) 22 (13.9)
Grade II (%) 38 (24.1)
Grade III (%) 98 (62.0)
Metastatic phase at diagnosis
Yes (%) 96 (34.5)






*number of lines of treatment.
**other histologies: angiomyolipoma (n = 2), ependymoma (n = 2),
nephroblastoma (n = 1), medulloblastoma (n = 1), inflammatory myofibroblastic
tumor (n = 1), chemodectoma (n = 1), giant cell tumor of bone (n = 1),
malignant schwannoma (n = 1), perineurioma (n = 1),
hemangioperycitoma (n = 1).
ASPS: alveolar soft parts sarcoma.
DFSP: dermatofibrosracoma protuberans.
DSRCT: desmoplastic small round cell tumor.
GIST: gastro-intestinal stromal tumor.
MPNST: malignant peripheral nerve sheath tumor.
SD: standard deviation.
TT: targeted therapy.
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coma with sorafenib (21%, n = 14). Some other combi-
nations showed signs of activity, but with two patients
or less per group (described in Table 3). The DCR was
59% at two months, 39% at four months, and 25% at six
months.
Follow-up and survival
Median follow-up since diagnosis was five years (range:
0,1 to 32,9, n = 234, 14 patients without follow-up data
and one patient with missing date of diagnosis). The
median PFS of the entire series was 4,1 months (95% CI
[3,2-4,8]). For STS (Figure 1A), median PFS was 3,8 months
(95% CI [2,4,9]). Figure 1B shows the PFS of patients
treated with TTs in third line and beyond. GIST and LMS,
the most two frequent subtypes, had a median PFS of
5,5 months (95% CI [4,4-8,1]) and 2,9 months (95% CI
[2,1-4,6]) respectively (Figure 1C and D). Forty-eight
patients died (20%), of underlying cancer in 98% of cases
(47 patients). One patient died from a massive pulmo-
nary embolism during treatment with sunitinib, in the
context of an intra-cardiac metastasis of a high-grade
Table 2 Targeted therapy by histotypes
Targeted therapy N % Histotype 1 n (%) Histotype 2 n (%) Histotype 3 n (%) Histotype 4 n (%) Histotype 5 n (%)
Sorafenib (1) 125 45 GIST 31 (25) LMS 22 (18) AS 14 (11) Uterine LMS 8 (6) Liposarcoma 8 (6)
Suntinib (2) 67 24 LMS 9 (13) Ewing 8 (12) SS 8 (12) Unclassified S 8 (12) Uterine LMS 4 (6)
Imatinib 23 8 Chordoma 8 (35) AF 4 (17) DFSP 4 (17) Epithelioid S 2 (9) ─ ─
Sirolimus-cyclophosphamide 18 6 OsteoS 8 (44) ChondroS 5 (27) AS/chordoma/lipoS/Ewing/SFT 1 each (6) ─ ─ ─ ─
Everolimus (3) 10 4 GIST 3 (30) LMS 3(30) KS/MPNST/SS 1 each (10) Other 1(10) ─ ─
Bevacizumab (4) 9 3 Other 5 (56) MFST 2 (22) AS 1 (11) Epithelioid S 1 (11) ─ ─
Sirolimus alone 5 2 OsteoS 2 (40) PEComa 1 (20) other 1 (20) ─ ─ ─ ─
Targeted therapies with less than 5 patients are not described in this table.
(1) alone in 120 cases, combination in 5 cases.
(2) alone in 66 cases, combination in 1 case.
(3) alone in 7 cases, combination in 3 cases.









MPNST: malignant peripheral nerve sheath tumor.
OsteoS: osteosarcoma.
SFT: solitary fibrous tumor.
SS: synovial sarcoma.

















Table 3 Description of responses by histotypes and targeted therapy
TT1 n % CR PR RR (%) TT2 n % CR PR RR (%) Other PRs (n)
Total 278* 3 22 0 5 5
GIST 39 sorafenib 31 79 0 3 10 nilotinib 3 8 0 0 0 ─
Leiomyosarcoma 36 sorafenib 22 61 0 3 14 sunitinib 9 25 0 2 22 ─
Angiosarcoma 18 sorafenib 14 78 0 3 21 sunitinib 2 11 0 1 50 ─
Unclassified sarcoma 15 sunitinib 8 53 0 1 13 sorafenib 5 33 0 0 0 ─
Chordoma 15 imatinib 8 53 0 0 0 sunitinib 3 20 0 0 0 erlotinib (1)
Osteosarcoma 15 sirolimus 10 67 0 0 0 sorafenib 3 20 0 0 0 ─
Synovialosarcoma 15 sunitinib 8 53 0 4 50 sorafenib 3 20 0 0 0 pazopanib (1)
Ewing / PNET 14 sunitinib 8 57 1 0 13 sorafenib 2 14 0 0 0 sirolimus + cyclop (1)
Chondrosarcoma 12 sirolimus 5 42 0 0 0 sorafenib 3 25 0 0 0 ─
Uterine leiomyosarcoma 12 sorafenib 6 50 0 1 17 sunitinib 4 33 0 0 0 ─
Liposarcoma 12 sorafenib 7 58 0 0 0 sunitinib 3 25 0 0 0 ─
Solitary fibrous tumor 10 sorafenib 3 30 0 0 0 sunitinib 2 20 0 0 0 beva + TMZ (1)
Epithelioid sarcoma 9 sorafenib 2 22 0 1 50 sunitinib 2 22 0 0 0 beva + pacli (1)
MPNST 8 sorafenib 4 50 0 0 0 sunitinib 2 25 0 1 50 ─
ASPS 8 sorafenib 5 63 0 2 40 sunitinib 3 38 0 0 0 ─
DSRCT 6 sorafenib 3 50 0 0 0 sunitinib 3 50 0 0 0 ─
AF 6 imatinib 4 67 0 0 0 sorafenib 1 17 0 1 100 ─
DFSP 5 imatinib 4 80 1 2 75 sunitinib 1 20 0 0 0 ─
PEComa 4 temsirolimus 2 50 1 1 100 sirolimus 1 25 0 0 0 ─
Rhabdomyosarcoma 3 sunitinib 2 67 0 0 0 sorafenib 1 33 0 0 0 ─
KS 1 everolimus 1 100 0 1 100 NA ─ ─ ─ ─ ─ ─
Low grade ESS 1 sorafenib 1 100 0 0 0 NA ─ ─ ─ ─ ─ ─
Phyllode tumor 1 sunitinib 1 100 0 0 0 NA ─ ─ ─ ─ ─ ─
Other (including benign tumors) 13 ND ─ ─ ─ ─ ND ─ ─ ─ ─ ─ ─
Complete and partial responses are indicated in bold.
*represents the total number of treatment lines (some patients had several lines of targeted therapy).
TT1 is the most frequent targeted therapy, TT2 is the second most frequent targeted therapy.
AF: aggressive fibromatosis.





DSRCT: desmoplastic small round cell tumor.
ESS: endometrial stromal sarcoma.
GIST: gastro-intestinal stromal tumor.
KS: kaposi sarcoma.
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attributed to sunitinib by the investigator).
Toxicity of targeted therapies (Table 4)
Among the 278 lines of treatment, 208 (75%) patients
developed at least one AE during the follow-up. Gastro-
intestinal toxicity was observed in 125 (45%) patients:25% patients had diarrhea, 9% stomatitis, 5% nausea, 5%
vomiting, and 3% anorexia. Skin toxicities and hema-
tologic toxicities were present in 29 and 22% of patients
respectively. Other side effects (pulmonary, cardiac, and
neurologic) were rare and observed in less than 10% of
cases. These AEs were mostly grade 1–2 (42% of pa-
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Figure 1 Progression-free survival data. A. Progression-free survival for soft-tissue sarcoma (except GIST). B: Progression-free survival of the
patients in third line and after (number of previous chemotherapy >2). C: Progression-free survival of the GIST group. D: Progression-free survival
of the leiomyosarcoma group.
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and skin/infectious toxicities (5%). Only 14 patients (5%)
experienced grade 4 toxicity, in the majority of cases
these were hematologic toxicities (6 patients, 2%). As ex-
pected, sorafenib, sunitinib and imatinib had different
toxicity profiles, but overall, the rate of grade 3–4 AE
was similar between these three agents (36% with sorafe-
nib, 40% with sunitinib and 35% with imatinib). No toxic
death occurred during follow-up.
Discussion
Why off label use and how it is selected
Designing and conducting prospective clinical trials in very
rare tumors is challenging. After standard treatments, cyto-
toxic chemotherapies are often used in routine practice on
the basis of phase II trials without evidence from randomized
studies [10,11]. We anticipated that results of different phase
II trials of TT in different sarcomas would lead to similar
off-label use, and decided to analyze their impact on survival,
response rate and toxicities within a prospective registry.
In term of routine practice, OUTC’S program con-
firmed that most patients received TTs that have already
shown signs of activity in phase II clinical trials. More
than 74 therapeutic combinations were proposed. 38% of
the decisions were based on published data, 30% on per-
sonal communications, and 29% on biological hypothesis(Additional file 2: Table S2). Only 4% of TT treatments
had no scientific rationale. Similarly, treatment decision
was made mostly following discussion at MSB, which
works on a careful evaluation of benefit/risk balance for
these off-label TTs. Functioning and organization of
MSB in France seem comparable to other countries [32];
these data could therefore be extrapolated elsewhere.
Efficacy and safety of treatment
DCR was 59% at 2 months, median PFS was 4,1 months,
and 3,8 months when considering the STS group. This con-
firms that off-label TTs can be considered as active treat-
ments, according to the analysis reported by the EORTC
Soft Tissue and Bone Sarcoma Group [33]. Median OS is
not interpretable due to the group heterogeneity, and for the
same reason, median PFS should be interpreted with cau-
tion. Three CRs and 32 PRs were observed. The efficacy of
off-label TTs in this study is comparable to that reported in
previous publications: in a phase II study, Maki and col-
leagues observed a median PFS of 3,2 months with sorafenib
as a single agent in patients with recurrent or metastatic
STS [22]. Another phase II study with 48 patients with non-
GIST sarcomas reported one PR and ten SD at 16 weeks
with sunitinib single agent [23]. In PALETTE phase III study,
patients receiving pazopanib had a median PFS of
4,6 months. All these patients had a metastatic soft-tissue
Table 4 Toxicities
Total* GRADE**
N (%) 1 N (%) 2 N (%) 3 N (%) 4 N (%)
SORAFENIB (n = 116)
At least 1 toxicity reported 94 (81) ─ ─ ─ ─
Intestinal toxicity 63 (54) 26 (22) 27 (23) 13 (11) 0 (0)
Skin toxicity, infections 56 (49) 26 (22) 20 (18) 12 (10) 0 (0)
Hematologic toxicity 18 (16) 5 (4) 10 (9) 5 (4) 0 (0)
Neurologic toxicity 12 (10) 9 (3) 2 (2) 1 (1) 0 (0)
Cardiologic toxicity 10 (9) 4 (3) 4 (3) 2 (2) 0 (0)
Pulmonary toxicity 4 (3) 2 (2) 1 (1) 1 (1) 0 (0)
Renal toxicity 1 (1) 0 (0) 1 (1) 0 (0) 0 (0)
Other toxicities 67 (58) 19 (16) 34 (29) 19 (16) 1 (1)
SUNITINIB (n = 66)
At least 1 toxicity reported 49 (74) ─ ─ ─ ─
Intestinal toxicity 26 (39) 16 (24) 7 (11) 5 (8) 0 (0)
Hematologic toxicity 21 (32) 5 (8) 11 (17) 3 (5) 4 (6)
Skin toxicity, infections 12 (18) 6 (9) 6 (9) 1 (2) 0 (0)
Neurologic toxicity 6 (9) 2 (3) 1 (2) 2 (3) 1 (2)
Pulmonary toxicity 5 (8) 3 (5) 1 (2) 1 (2) 0 (0)
Cardiologic toxicity 3 (5) 3 (5) 0 (0) 0 (0) 0 (0)
Renal toxicity 1 (2) 0 (0) 0 (0) 0 (0) 1 (2)
Other toxicities 38 (58) 15 (23) 14 (21) 13 (20) 2 (3)
IMATINIB (n = 23)
At least 1 toxicity
reported
20 (87) ─ ─ ─ ─
Intestinal toxicity 12 (52) 6 (26) 4 (17) 1 (4) 1 (4)
Hematologic toxicity 6 (26) 2 (9) 2 (9) 2 (9) 0 (0)
Skin toxicity, infections 2 (9) 2 (9) 0 (0) 0 (0) 0 (0)
Neurologic toxicity 1 (4) 0 (0) 1 (4) 1 (4) 0 (0)
Pulmonary toxicity 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Cardiologic toxicity 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Renal toxicity 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other toxicities 17 (74) 4 (17) 12 (52) 3 (13) 0 (0)
SIROLIMUS + CYCLOPHOSPHAMIDE (n = 18)
At least 1 toxicity reported 9 (50) ─ ─ ─ ─
Intestinal toxicity 5 (28) 4 (22) 1 (6) 0 (0) 0 (0)
Hematologic toxicity 3 (17) 1 (6) 1 (6) 0 (0) 1 (6)
Pulmonary toxicity 2 (11) 1 (6) 0 (0) 0 (0) 1 (6)
Skin toxicity, infections 1 (6) 1 (6) 0 (0) 0 (0) 0 (0)
Neurologic toxicity 1 (6) 0 (0) 1 (6) 0 (0) 0 (0)
Renal toxicity 1 (6) 0 (0) 0 (0) 1 (6) 0 (0)
Cardiologic toxicity 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other toxicities 7 (39) 3 (17) 4 (22) 0 (0) 0 (0)
*number of lines of treatment.
**below are described the numbers and percentages of patients with at least one toxicity of each grade.
(a patient could have experienced several grades for the same type of toxicity).
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apy and had received up to 3 lines of prior treatment [24].
Median PFS of the LMS group was 2,9 months here. As a
comparison, in the phase II study by Mahmood et al., LMS
patients treated with sunitinib had a median PFS of
4,2 months [34]. The RR of GIST-patients treated with soraf-
enib was 10% in our population, compared to 13% in the
phase II trial by Kindler and colleagues [35]. In the sunitinib
phase II trial [23], among four patients with SS, only one
had a SD as best response. Here, among eight patients
treated with sunitinib for a SS, four had a PR, corre-
sponding to a RR of 50%. Hence, the analysis of this
registry confirms that TTs with activity in phase II trials
can also demonstrate activity of a similar magnitude in an
off-label setting, in a less selected population. Moreover,
the population included in clinical trials often received
fewer prior systemic therapies. For example, patients in-
cluded in the sunitinib trial had only received two lines of
treatment before inclusion [23], and only 63% of patients
had one or more prior line chemotherapy in the sorafenib
trial [22]. The reported AEs (mostly grade I or II) were
similar to those reported in clinical trials [22,23], even in
this non-selected population.
A useful method to collect information for off label
treatment
This study shows an original methodological approach to
collect information for off-label use of TT in rare tumors,
for patients who cannot be included in clinical trials, either
because of inappropriate inclusion criteria or because cli-
nical trials do not exist. Some histological subtypes are too
rare to get pharmaceutical companies interested in de-
veloping randomized trials. The major limitation of this
study is that it is only descriptive, not randomized and
therefore lacks a control arm. However, it confirms safety
of TTs in routine practice, and has practical interest, in
particular for therapeutic niches. The latest developments
in Ewing’s sarcoma tend to show that Insulin-like Growth
Factor 1 Receptor (IGF1R) targeting agents are promising
[36,37], but none was efficient enough to lead to a phase
III trial. Our case of CR with sunitinib opens the way
to the exploration of VEGFR and PDGFR pathways in
Ewing’s sarcoma. The inactivation of TSC1/TSC2 in
PEComa leads to increased mTOR complex 1 (TORC1)
activation [36,38]. In other reports [39,40], three patients
treated with sirolimus achieved PR, one patient had a PR
with temsirolimus and another one had a CR with the
same rapalog. Even if resistance to mTOR targeting
agent has been reported in this very rare pathology [41],
this new case of CR in the OUTC’S program with an
mTOR inhibitor is encouraging to engage in a prospec-
tive clinical trial.
Collection of additional molecular data was not planned
as part of this study. Patients were included between 2008and 2011, and very few molecular biology platforms were
able to perform tumor-sequencing analysis routinely at
this time. The question of treating patients according to
actionable genomic alterations in advanced malignancies
is currently being addressed in specific clinical trials, such
as the Profiler [42] and SHIVA [43] trials in France.Conclusions
In conclusion, this registry collected data on a large num-
ber of patients treated with off-label TTs in various sar-
coma subtypes. No major toxic or unusual side effects
were observed and efficacy was similar to that observed in
published trials. Discussion of cases by a MSB to de-
termine the legitimacy of such treatments ensures some
consensus among experts in the field, and gives the oppor-
tunity for heavily pre-treated patients access these new
agents. This methodological approach could be easily ex-
trapolated to other rare cancers, in the absence of clinical
trials.Additional files
Additional file 1: Participating centers.
Additional file 2: Table S1. First line therapy. Table S2. rationale of the
targeted therapy prescription.
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